World’s first, Aopeng Medical completes clinical trial of assisted robotic intervention in the peripheral artery of the iliac artery in humans

Effectively fill the gaps in the intervention robot market

Aopeng Medical’s ALLVAS ™ endovascular surgical robot is the first peripheral arterial intervention robot-platform with independent intellectual property rights in China. Its core technology covers robot architecture design, robotic arm and actuator process design, force feedback mechanism, software algorithm and automated surgery, systems integration, etc. -technological look. Earlier this year, Aopeng Medical completed the world’s first human clinical trial of robotic-assisted endovascular aortic repair of thoracic aortic aneurysm and abdominal aortic aneurysm.

Traditional surgical treatment has many side effects, such as high trauma, high risk, difficulty, and multiple complications. In comparison, Aopeng’s endovascular intervention robot, ALLVAS ™, can achieve precise positioning using digital technology, which meets the specific needs of each patient. It is also expected to reduce the radiation dose received by the operator by more than 90% and improve the precision of surgical manipulation, thus helping physicians to achieve higher efficiency and more satisfactory effects in clinical practice.

Vast long-term opportunities for endovascular intervention robots

Peripheral vascular intervention is a minimally invasive endovascular procedure to treat occlusive and stenotic lesions caused by atherosclerosis of the extremities, which currently affects approximately 20 million people in China. With 2.3 million procedures performed annually worldwide, its medical device market is nearly $ 5 billion. In the future, the application of endovascular intervention robots in the field of peripheral vascular and venous interventional procedures is a promising direction of development for the industry, both in Chinese and international markets.

Based on public data, the number of patients with peripheral vascular disease in China is huge. It is equal to the sum of coronary patients and diabetic patients. The coronary stent to peripheral stent ratio is 3: 2 in foreign countries, while this ratio is 10: 1 in China. According to this ratio, the peripheral arterial stents market is expected to grow to the same size as the coronary arterial stents market. In China, patients with atherosclerosis of the extremities are not adequately treated. However, the basic routines for performing minimally invasive procedures have not changed substantially, and there are still two major issues in the industry, such as radiation exposure of physicians and the difficulty of an operation. precise. The emergence of surgical robots allows remote and delicate surgical operations to be performed, thus revolutionizing minimally invasive endovascular procedures. In addition, by combining robotics and artificial intelligence technology, the long-term view of AI diagnostics, AI design of the surgical plan, semi-automatic and even fully automatic surgical operation by robot will be achievable.

Aopeng Medical has filed 36 patents for the ALLVAS ™ endovascular intervention robot, which allows it to reach the pinnacle of technological innovation and thus establish its leading position in the endovascular intervention robot industry.

SOURCE Aopeng Medical


Source link

Comments are closed.